However, Widera said that the push toward the antiamyloid medications — which also include lecanemab (Leqembi, Biogen and Eisai ... is a consultant for Cerveau Technologies, a company ...

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Irhythm Technologies (IRTC – Research Report), Vir ...

Biogen is continuing to thin its pipeline, dropping a phase 2 program acquired in the $7.3 billion Reata Pharmaceuticals buyout and kicking early-stage Alzheimer’s and Parkinson’s prospects ...

Biogen expects Leqembi and new rare disease and depression treatments to help offset revenue lost from multiple sclerosis products.

Biogen's Q4 2024 earnings showed slight revenue growth but Wall Street remains unimpressed due to weak guidance and declining key drug franchises. Leqembi's commercial performance is disappointing ...

Biogen posted fourth-quarter revenue and profit that topped expectations as its cost cuts showed progress and new products, including its breakthrough Alzheimer's treatment Leqembi, saw growth.

Biogen (NASDAQ:BIIB) shares traded flat in the premarket on Wednesday after the Alzheimer’s drug developer reported better-than-expected Q4 2024 financials while its full-year outlook ...

Biogen expects full-year 2025 total revenue to decline by a mid-single digit percentage. The company’s stock was down about 6% at 10 a.m. on Wednesday with shares priced at around $131 apiece.

Investors with a lot of money to spend have taken a bullish stance on Biogen BIIB. And retail traders should know. We noticed this today when the trades showed up on publicly available options ...